NCT02631954View on ClinicalTrials.gov

Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

November 30, 2015

Conditions
Aspergillus InfectionsCandida InfectionsFungal Infections
Interventions
DRUG

Vorico Injection 200mg(Voriconazole)

Vorico Injection 200mg(Voriconazole) to administered intravenously once

DRUG

Vfend®(Voriconazole) IV 200mg

Vfend®(Voriconazole) IV 200mg to administered intravenously once

Trial Locations (1)

22332

Inha University Hospital, Incheon

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY